Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Market Resilience | Thermo Fisher Scientific demonstrates resilience in the Life Science Tools & Diagnostics sector, consistently exceeding guidance and navigating market challenges |
Financial Strength | Explore Thermo Fisher's solid financial performance, with EPS projections of $21.77 for the current fiscal year and $23.86 for the following yea |
Global Growth Outlook | Delve into Thermo Fisher's growth strategies, including its promising prospects in the China market and the potential impact of stimulus efforts |
Analyst Perspectives | Learn about mixed analyst views on Thermo Fisher's future, with price targets ranging from $600 to $664, reflecting both optimism and caution |
Metrics to compare | TMO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTMOPeersSector | |
---|---|---|---|---|
P/E Ratio | 34.8x | −10.8x | −0.6x | |
PEG Ratio | 7.63 | −0.10 | 0.00 | |
Price/Book | 4.4x | 2.2x | 2.6x | |
Price / LTM Sales | 5.0x | 3.1x | 3.2x | |
Upside (Analyst Target) | 17.4% | 37.9% | 48.6% | |
Fair Value Upside | Unlock | 10.8% | 7.0% | Unlock |